G. Kristiansen et al., Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer, EUR J CANC, 37(9), 2001, pp. 1089-1095
Overexpression of the c-erbB2 protein is observed in a variety of malignanc
ies including non-small cell lung cancer (NSCLC). We aimed to determine the
rate of c-erbB2-overexpression in our tumour collection and to clarify its
correlation with the chromosomal status at the c-erbB2 locus 17q21 in NSCL
C. Eighty-nine NSCLC were analysed immunohistochemically using a polyclonal
c-erbB2 antibody (DAKO). The staining was scored according to the guidelin
es of the Clinical Trial Assay recommendations (0-3 +). Of these, 44 cases
were also analysed by comparative genomic hybridisation (CGH). Overexpressi
on was observed in 37% of the cases (score > 1) which was associated with h
igher disease stages and a positive nodal status in adenocarcinomas. Chromo
somal gains at 17q21 were clearly correlated with overexpression of the gen
e (P = 0.009). In addition, there was a highly significant correlation betw
een the c-erbB2 expression comparing the whole section immunostaining analy
sis and a 127 lung tumour tissue array which included 74 of the 89 cases th
at were analysed by the classical procedure. We conclude that c-erbB2 is a
marker of tumour progression in NSCLC which can be observed on protein leve
l and reflects chromosomal alterations at 17q21. (C) 2001 Elsevier Science
Ltd. All rights reserved.